Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

Aman U. Buzdar, George R. Blumenschein, Terry L. Smith, Kimberly C. Powell, Gabriel N. Hortobagyi, Hwee Y. Yap, Frank C. Schell, Brian C. Barnes, Frederick C. Ames, Richard G. Martin, Evan M Hersh

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

Original languageEnglish (US)
Pages (from-to)384-389
Number of pages6
JournalCancer
Volume53
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Fluorouracil
Doxorubicin
Cyclophosphamide
Bacillus
Breast Neoplasms
Survival
Random Allocation
Immunotherapy
Vaccines
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. / Buzdar, Aman U.; Blumenschein, George R.; Smith, Terry L.; Powell, Kimberly C.; Hortobagyi, Gabriel N.; Yap, Hwee Y.; Schell, Frank C.; Barnes, Brian C.; Ames, Frederick C.; Martin, Richard G.; Hersh, Evan M.

In: Cancer, Vol. 53, No. 3, 1984, p. 384-389.

Research output: Contribution to journalArticle

Buzdar, Aman U. ; Blumenschein, George R. ; Smith, Terry L. ; Powell, Kimberly C. ; Hortobagyi, Gabriel N. ; Yap, Hwee Y. ; Schell, Frank C. ; Barnes, Brian C. ; Ames, Frederick C. ; Martin, Richard G. ; Hersh, Evan M. / Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. In: Cancer. 1984 ; Vol. 53, No. 3. pp. 384-389.
@article{30587b45ef9a40daa531f15e93e97061,
title = "Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial",
abstract = "Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72{\%} at 3 years.",
author = "Buzdar, {Aman U.} and Blumenschein, {George R.} and Smith, {Terry L.} and Powell, {Kimberly C.} and Hortobagyi, {Gabriel N.} and Yap, {Hwee Y.} and Schell, {Frank C.} and Barnes, {Brian C.} and Ames, {Frederick C.} and Martin, {Richard G.} and Hersh, {Evan M}",
year = "1984",
doi = "10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G",
language = "English (US)",
volume = "53",
pages = "384--389",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

AU - Buzdar, Aman U.

AU - Blumenschein, George R.

AU - Smith, Terry L.

AU - Powell, Kimberly C.

AU - Hortobagyi, Gabriel N.

AU - Yap, Hwee Y.

AU - Schell, Frank C.

AU - Barnes, Brian C.

AU - Ames, Frederick C.

AU - Martin, Richard G.

AU - Hersh, Evan M

PY - 1984

Y1 - 1984

N2 - Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

AB - Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette‐Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow‐up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease‐free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease‐free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease‐free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease‐free survival was 72% at 3 years.

UR - http://www.scopus.com/inward/record.url?scp=0021359951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021359951&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

DO - 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G

M3 - Article

C2 - 6362814

AN - SCOPUS:0021359951

VL - 53

SP - 384

EP - 389

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -